Proactive Investors
15 Jul 2026, 19:35 UTC · 8w ago
Verdict
Headline takes no side. We score JNJ +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Johnson & Johnson reported Q2 worldwide sales of $584 million for Spravato, a 25% increase from the previous quarter.
More positive than 91% of claims this week
Jefferies analysts state that Spravato's success supports the commercial viability of the broader psychedelic sector for hard-to-treat mental health disorders.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 85% of claims this week
Compass Pathways plans to complete a rolling New Drug Application for COMP360 in Q4 2026, targeting a potential approval by year-end.
So whatThis represents a concrete, near-term regulatory catalyst that could lead to a commercial launch in early 2027.
More positive than 77% of claims this week
Johnson & Johnson has guided for Spravato peak annual sales of up to $5 billion.
So whatHigh peak sales guidance signals a massive addressable market for the category, though it is a long-term projection.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Reported strong second-quarter sales for Spravato, showing 25% growth and progress toward annual targets.
More positive than 76% of ticker scores this week
The company is seeing a positive read-through from J&J's Spravato sales and has upcoming clinical milestones.
More positive than 76% of ticker scores this week
Positive sector outlook and an upcoming NDA completion for COMP360 provide growth potential.
More positive than 76% of ticker scores this week
The company is listed as a beneficiary of the positive commercial performance of Spravato in the psychedelics sector.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
3h ago
More positive than 35% of relationship scores this week
[mutual] Both are psychedelic drug developers competing in the mental health disorder market.
More positive than 35% of relationship scores this week
[mutual] Both are psychedelic drug developers competing in the mental health disorder market.
More positive than 14% of relationship scores this week
[mutual] JNJ's Spravato competes for the same treatment-resistant depression market as ATAI's BPL-003.
More positive than 14% of relationship scores this week
[mutual] JNJ's Spravato competes for the same treatment-resistant depression market as CMPS's COMP360.
More positive than 14% of relationship scores this week
[mutual] JNJ's Spravato competes for the same treatment-resistant depression market as CYBN's psychedelic therapies.
+5.5%
Price agrees with the score
$267.71 vs $253.85 close before publication (Jul 14) · not market-adjusted
JNJ chart →
